Forte Biosciences Q1 net loss $0.16/shr; cash $30.4M; FB102 SAD completed, MAD ongoing

Forte Biosciences, Inc.

2024-Q1 EPS reported -$0.16

Net loss $7.4M ($0.16/shr) vs $6.8M ($0.32/shr) in Q1 2023; weighted avg shares 46.1M (incl. pre-funded warrants).
R&D expense $4.4M (down $0.4M); G&A $3.5M (up $1.4M on legal/professional costs).
Cash & equivalents $30.4M at Mar 31, 2024, down from $37.1M at Dec 31, 2023.
FB102 Phase 1 SAD completed; MAD cohorts expected to complete mid-2024; patient studies planned before year-end.
Company updated corporate presentation (Exhibit 99.2) for investor meetings.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Forte Biosciences, Inc. reported the quarter ended March 31, 2024 results: net income $(7,420 ), EPS $(0.16 ).

Period: the quarter ended March 31, 2024
Net income: $(7,420 )
EPS: $(0.16 )
Result: reported results

Exact text from the filing

On May 13, 2024, Forte Biosciences, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Forte Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-137210

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.